AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Queenan, A. M.
Right arrow Articles by Quinn, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Queenan, A. M.
Right arrow Articles by Quinn, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2006, p. 3485-3487, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00363-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

SME-3, a Novel Member of the Serratia marcescens SME Family of Carbapenem-Hydrolyzing ß-Lactamases

Anne Marie Queenan,1* Wenchi Shang,1 Paul Schreckenberger,2 Karen Lolans,3 Karen Bush,1 and John Quinn3

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Raritan, New Jersey,1 Loyola University Medical Center, Maywood, Illinois,2 CIDRI, John H. Stroger Hospital of Cook County, Chicago, Illinois3

Received 24 March 2006/ Returned for modification 12 May 2006/ Accepted 14 July 2006

Imipenem-resistant Serratia marcescens isolates were cultured from a lung transplant patient given multiple antibiotics over several months. The strains expressed SME-3, a ß-lactamase of the rare SME carbapenem-hydrolyzing family. SME-3 differed from SME-1 by a single amino acid substitution of tyrosine for histidine at position 105, but the two ß-lactamases displayed similar hydrolytic profiles.


* Corresponding author. Mailing address: Antimicrobial Agents Research Team, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202 South, OMP Research B210, Raritan, NJ 08869. Phone: (908) 704-5515. Fax: (908) 707-3501. E-mail: aqueenan{at}prdus.jnj.com.


Antimicrobial Agents and Chemotherapy, October 2006, p. 3485-3487, Vol. 50, No. 10
0066-4804/06/$08.00+0     doi:10.1128/AAC.00363-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.